Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis. (Q33423275)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19327167%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

title

Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19327167%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19327167%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

author name string

Virginia L Stauffer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19327167%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Ilya Lipkovich

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19327167%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Vicki Poole Hoffmann

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19327167%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Alexandra N Heinloth

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19327167%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Bruce J Kinon

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19327167%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

publication date

28 March 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19327167%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19327167%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19327167%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

page(s)

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19327167%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1186/1471-244x-9-12

25 January 2020

exact match

0 references

cites work

Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667505

Pharmacological management of atypical antipsychotic-induced weight gain.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667505

Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667505

Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667505

Behavioral therapy for weight loss in patients with schizophrenia.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667505

Interventions to reduce weight gain in schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667505

Eating and weight related cognitions in people with Schizophrenia : a case control study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667505

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667505

Current options in the management of olanzapine-associated weight gain

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667505

Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667505

H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667505

Antipsychotic-induced weight gain: a comprehensive research synthesis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667505

The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667505

Open label study of the effect of amantadine on weight gain induced by olanzapine

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-12

Amantadine for weight gain associated with olanzapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-12

Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-12

Cognitive behavioural therapy for weight gain associated with antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-12

Early predictors of substantial weight gain in bipolar patients treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-12

Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-12

Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-12

Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-12

Appropriate intervention strategies for weight gain induced by olanzapine: a randomized controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-12

Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-12

A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-12

Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-12

Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-12

Effect of amantadine on weight gain during olanzapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-12

Weight loss with topiramate

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-12

Metformin for weight loss in pediatric patients taking psychotropic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-12

Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-12

Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-12

A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-12

Mood stabilization and weight loss with topiramate

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-12

The epidemiology of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-12

Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667505

Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667505

Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667505

Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667505

Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667505

Medical risk in patients with bipolar disorder and schizophrenia

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19327167

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-244X-9-12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19327167%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

25 January 2020

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-244x-9-12

9 September 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19327167%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1 reference